ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Phase 4

Recruiting

• Conditions: Aortic Valve Stenosis; Heart Failure
• Interventions: Drug: Enavogliflozin; Drug: Standard-of-Care

• Registration Number: NCT05672836
• Lead Sponsor: Duk-Woo Park, MD

Brief Summary

The goal of this trial is to to determine whether use of a novel SGLT2 inhibitor, Enavogliflozin 0.3 mg once daily is superior to placebo, when added to standard-of-care, in reducing the composite of major cardiovascular events and Heart Failure events (hospitalization for Heart Failure or urgent Heart Failure visit) among patients who underwent transcatheter aortic valve replacement for severe aortic stenosis and with heart failure with preserved ejection fraction.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-01-01
• Study First Submitted QC: 2023-01-04
• Study First Posted: 2023-01-05
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-17
• Study Start: 2024-12-18
• Last Update Posted: 2024-12-19
• Primary Completion: 2026-12
• Study Completion: 2027-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1040

Inclusion Criteria

1. Patients aged ≥19 with symptomatic aortic stenosis who underwent successful transcatheter aortic valve replacement (TAVR)* (either native valve or valve in valve with any approved/marketed device).

* A successful TAVI is defined as device success according to the VARC-2(Valve Academic Research Consortium 2) and VARC-3 criteria:

1. correct positioning of a single prosthetic heart valve into the proper anatomical location AND

2. intended performance of the prosthetic heart valve (mean aortic valve gradient <20 mmHg, peak velocity <3 m/s, no moderate or severe prosthetic valve regurgitation) AND

3. absence of periprocedural complications (any type of stroke, life-threatening bleeding, acute coronary artery obstruction requiring intervention, major vascular complication requiring intervention, unresolved acute valve thrombosis, or any requirement of a repeat procedure).

4. Heart Failure with Mildly Reduced or Preserved Ejection Fraction

5. Left ventricular ejection fraction (LVEF) ≥40%

6. structural heart disease_Left ventricular hypertrophy (LVH) or Left atrial enlargement

   A. Left ventricular hypertrophy (LVH) with septal thickness or posterior wall thickness ≥ 1.1 cm or

   B. Left atrial (LA) enlargement with at least one of the following: LA width (diameter) ≥3.8 cm or LA length ≥ 5.0 cm, or LA area ≥ 20cm2, or LA volume ≥ 55mL or LA volume index ≥ 29mL/m.

7. NT-proBNP ≥ 300 pg/mL (for patients without ongoing atrial fibrillation) or NT-proBNP must be ≥ 600 pg/mL (for patients with ongoing atrial fibrillation).

8. Patients who voluntarily participated in the written agreement

Exclusion Criteria

1. Acute decompensated Heart Failure (exacerbation of chronic Heart Failure) requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support, or hemodynamic instability following the transcatheter aortic valve replacement procedure.

2. Currently receiving therapy with an SGLT2 inhibitor within 4 weeks prior to randomization; discontinuation of current use of SGLT2 inhibitor for the purposes of study enrolment is not permitted.

3. Known allergy, hypersensitivity, or previous intolerance to an SGLT2 inhibitors.

4. HF with reduced ejection fraction (LVEF <40%).

5. Type 1 diabetes mellitus or diabetes ketoacidosis.

6. Chronic cystitis and/or recurrent urinary tract infection (≥2 times within 1 year).

7. Stroke or transient ischemic attack within 12 weeks prior to enrollment.

8. Symptomatic persistent hypotension and/or a systolic blood pressure (SBP) < 95 mm Hg at screening or at randomization.

9. SBP ≥180 mmHg irrespective of treatment or SBP ≥160 mmHg with at least ≥3 antihypertensive drugs at screening or randomization.

10. Heart failure due to any of the following causes; known infiltrative cardiomyopathy (e.g. amyloid, sarcoid, lymphoma, endomyocardial fibrosis, haemochromatosis, Fabry disease), active myocarditis, constrictive pericarditis, cardiac tamponade, known hypertrophic obstructive cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVD), or uncorrected primary valvular disease.

11. Severe renal insufficiency (eGFR <30 ml/min/1.73 m2 of body-surface area based on the Modification of Diet in Renal Disease (MDRD) formula) or end-stage renal disease or requiring dialysis at the time of screening.

12. Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices, coagulopathy) or serum levels of transminases or alkaline phosphatase more than two times the upper limit of normal at screening.

13. Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months, or significant chronic pulmonary disease in the Investigator's opinion, or primary pulmonary arterial hypertension.

14. Current or suspicious malignancy or history of malignancy within 5 years

15. Uncontrolled anaemia or haemoglobin <9g/dl

16. Uncontrolled hypothyroidism or arrhythmia or tachycardia

17. Current ongoing alcoholic or drug addict

18. Subjects with non-cardiac co-morbidities with life expectancy less than 12 months

19. Planned major high-risk operation after transcatheter aortic valve replacement (TAVR)

20. Women of childbearing age who have not reached a consensus on the use of highly effective contraception. Pregnancy or breastfeeding.

21. Participation in other clinical trials, However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;

    • Participating in the observational study expected no effect on the safety and/or effectiveness evaluation of this trial.
    • Screening failed before any interventional factor is involved.
    • Participants who have completed their involvement in clinical trials and have surpassed a 4-week period since their last administration of the investigational drug.
    • Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Enavogliflozin Group	Enavogliflozin	0.3 mg 1 tablet once daily
placebo as add-on to standard of care treatment group	Standard-of-Care	Placebo matching enavogliflozin

Primary Outcome Measures

Name	Time	Method
Time from randomization to first occurrence of a composite of major adverse cardiovascular events* or hospitalization for heart failure	12 months	Time from randomization to the first occurrence of a composite of major adverse cardiovascular events\* or hospitalization for heart failure at 12 months after randomization.; \*Major adverse cardiovascular events included death from any causes, nonfatal myocardial infarction, or nonfatal stroke.; A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.

Secondary Outcome Measures

Name	Time	Method
Event rate of nonfatal stroke	12 months
Event rate of Composite renal endpoint	12 months	Composite renal endpoint, defined as time to first occurrence of (1) chronic dialysis; (2) renal transplantation; (3) sustained reduction of ≥40% in estimated glomerular filtration rate (GFR); or (4) sustained estimated GFR \<15 mL/min/1.73 m2 for patients with baseline estimated GFR ≥30 mL/min/1.73 m2.
Event rate of Rehospitalization for any reason	12 months
Changes in measures of cardiac volume and function assessed by serial echocardiography	12 months	left ventricular ejection fraction(LVEF), LV end-diastolic volume index (LVEDVI), LV end-systolic volume index (LVESVI), left atrial volume index (LAVI), and the ratio of early transmitral Doppler velocity/early diastolic annular velocity (E/e')
Changes in New York Heart Association (NYHA) functional class and the Kansas City Cardiomyopathy Questionnaire (KCCQ) summary score	12 months	New York Heart Association (NYHA) Functional Classification on a scale from I to IV, with higher scores indicating severe symptoms and physical limitations associated with heart failure.; the Kansas City Cardiomyopathy Questionnaire (KCCQ)on a scale from 0 to 100, with higher scores indicating fewer symptoms and physical limitations associated with heart failure.
Serial change in NT-proBNP	12 months	N-terminal (NT)-pro hormone BNP (NT-proBNP)
Event rate of death from any cause	12 months
Event rate of hospitalization for heart failure	12 months
Event rate of nonfatal myocardial infarction	12 months
Event rate of the safety events	12 months	The safety events are defined as; * Serious adverse events; * Adverse events leading to treatment discontinuation; * Adverse events of special interest(AESI); * Hypoglycemia, genitourinary infections, hepatic injury, decreased renal function, ketoacidosis, events leading to lower limb amputation; * AESIs leading to treatment discontinuation

Trial Locations

Locations (1)

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of